Artiva AlloNK shows CAR T-like responses in autoimmune diseases

Key Highlights

• AlloNK + rituximab showed clinical responses comparable to autologous CAR T-cell therapy in 31 rheumatologic patients.
• 71% ACR50 response observed in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up.
• No RA patients relapsed or required new immunomodulatory agents post-treatment.
• Positive experience reported in the first patient with severe Sjögren disease treated with AlloNK + rituximab.
• AlloNK achieved deep, consistent B-cell depletion comparable to CD19 CAR T-cell therapies.
• A favorable safety profile was demonstrated in immune-mediated diseases.
• Artiva plans to initiate a Phase 3 registrational trial for AlloNK in refractory RA in 2026.
• Five abstracts detailing AlloNK data will be presented at the EULAR 2026 Congress.